Introduction {#Sec1}
============

Multiple sclerosis (MS) is a chronic disorder of the central nervous system with inflammatory demyelination and axonal degeneration \[[@CR1]\]. The disease usually starts between the ages of 20 and 40 years, and by the age of 55 years, about half of the patients need unilateral assistance to walk \[[@CR2]\]. The disease progresses slowly, and clinical scales currently used are not sensitive enough to quantify progression \[[@CR3]\]. Using surrogate markers of progression can shorten the duration of clinical trials in progressive MS.

¹H-magnetic resonance spectroscopy (¹H-MRS) of the brain in MS patients can detect changes in cell metabolites in both focal lesions and normal-appearing white matter (NAWM) \[[@CR4]\]. Compared to controls, N-acetylaspartate (NAA) concentrations in MS patients are lower both in the lesions and in NAWM, whereas creatine (Cr) concentrations are equal to slightly increased \[[@CR5]\]. NAA is a marker of neuroaxonal metabolism and integrity, and reductions in the white matter are due to axonal dysfunction or loss. It has been suggested that whole-brain NAA decline rates in patients with MS may predict future disease course \[[@CR6]\]. Cr is present in neurons, astrocytes and oligodendrocytes, and elevations in white matter of MS patients can be due to axonal transection, astrocytic proliferation, and demyelination. Because absolute concentrations of metabolites with ¹H-MRS are difficult to interpret, the NAA/Cr ratio is often used as a valid surrogate marker of 'cerebral tissue integrity' \[[@CR5]\]. Decreases in NAA/Cr, which in MS patients are found in lesions and NAWM, are indicative of neuroaxonal disturbance, oligodendroglial disturbance, or astrocytic proliferation. The third metabolite well observable in long TE ¹H-MRS is choline (Cho), which is regarded as a marker of glial proliferation \[[@CR7]\].

Next to validity, good surrogate markers need to be reliable, especially when used for monitoring white matter integrity in longitudinal studies. In this study we investigated the reproducibility of NAA/Cr ratios obtained with 2D spectroscopic imaging at two different levels of the centrum semiovale within a time span of 4 weeks in patients with clinically stable MS.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

All patients co-operated in the study with informed consent and local medical ethical committee approval. Thirty-five patients participated in the study. Patients were randomly divided in two groups. All patients had clinically definitive MS with a relapsing remitting or secondary progressive disease course \[[@CR8], [@CR9]\]. None of the patients was using immunomodulatory medication. Patients were relapse free for at least 4 weeks and had not taken corticosteroids 4 weeks prior to the first MRI and during the study period. Disability was assessed with the Expanded Disability Status Scale (EDSS), which gives a score ranging from 0 to 10 with higher scores, indicating more disability \[[@CR10]\].

^1^H-MR spectroscopy {#Sec4}
--------------------

MRI scans of the brain were obtained at baseline and after 4 weeks at a 3.0-T unit (Philips, Best, The Netherlands). ^1^H-MR spectroscopic imaging was preceded by the acquisition of a transverse multiple-slice MRI series in order to position the volume of interest (VOI). The standard transmitter/receiver coil was used, and the volume localisation was done by a combination of slice selection and 2D phase encoding with outer volume suppression with 12 rest slabs. All scan parameters were the same: TE =144 ms, TR =2.5 s, FOV =230 mm, slice thickness =20 mm, matrix =24×24, and turbo factor =3. Total scan time was around 8 min.

Group 1 was scanned around the lateral ventricles with some cerebrospinal fluid included in the VOI (Fig. [1](#Fig1){ref-type="fig"}a). Group 2 was scanned above the lateral ventricles with no cerebrospinal fluid included in the VOI (Fig. [1](#Fig1){ref-type="fig"}b). Individual anatomic landmarks were used for voxel repositioning. Fig. 1Sagittal MRI images showing the volume of interest scanned in group 1 (**a**) and group 2 (**b**) with an axial image (**c**) displaying the grey (inner 12) and white matter (outer 12 in both hemispheres) voxels

To select voxels that mainly contained grey matter, 12 spectroscopic imaging (SI) voxels were selected in the midline grey matter in each subject (Fig. [1](#Fig1){ref-type="fig"}c). To select voxels that mainly contained white matter, 24 SI voxels were selected (12 in each hemisphere) in the deep white matter in each subject (Fig. [1](#Fig1){ref-type="fig"}c). Metabolite peak areas of NAA and Cho were determined with the manufacturer\'s software (Philips SPECTROVIEW) and are expressed as ratios to Cr. All voxels were visually checked for quality of the spectra and quality of the fitting of the peak areas and rejected if inaccurate according to the opinion of the two observers.

In every patient the NAA/Cr and Cho/Cr ratios per voxel were determined, and average ratios of the voxels in grey and white matter were calculated.

Statistical analysis {#Sec5}
--------------------

Reproducibility was tested by a coefficient of variation $\documentclass[12pt]{minimal}
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\begin{document}$$\left( {{\text{CV}} = {{100 * {\text{standard}}\,{\text{deviation}}\,{\text{of}}\,{\text{the}}\,{\text{mean}}\,{\text{difference}}} \mathord{\left/ {\vphantom {{100 * {\text{standard}}\,{\text{deviation}}\,{\text{of}}\,{\text{the}}\,{\text{mean}}\,{\text{difference}}} {\left[ {\surd 2 * {\text{pooled}}\,{\text{mean}}\,{\text{values}}} \right]}}} \right. \kern-\nulldelimiterspace} {\left[ {\surd 2 * {\text{pooled}}\,{\text{mean}}\,{\text{values}}} \right]}}} \right)$$\end{document}$ \[[@CR11]\]. Changes in grey matter and white matter after 4 weeks and differences between baseline grey and white matter NAA/Cr ratios in patients were tested with paired t-tests. Differences between baseline grey matter and white matter NAA/Cr ratios of the two VOIs were tested with unpaired t-tests.

Results {#Sec6}
=======

Baseline characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. Patients were scanned after a mean ± standard deviation of 27.3±2.2 days. The mean number of excluded voxels was 1.51±2.93 for NAA/Cr and 4.54±5.40 for Cho/Cr (out of 36 voxels). White matter NAA/Cr and Cho/Cr ratios were higher than grey matter ratios (Table [2](#Tab2){ref-type="table"}). The mean NAA/Cr did not change in either white matter or grey matter in both groups after 4 weeks (Table [2](#Tab2){ref-type="table"}). The NAA/Cr ratios in grey and white matter were significantly higher in the group scanned with the ventricles partially included (p\<0.001). Mean Cho/Cr in white and grey matter was 1.14 and 1.07 in group 1 and 0.98 and 0.92 in group 2 (p\<0.001). Overall, the CV for NAA/Cr and Cho/Cr was 3.5% and 4.1% for white matter and 4.8% and 5.2% for grey matter. In group 1, the CVs of NAA/Cr in white matter and grey matter were 4.3% and 5.7%, and in group 2, 2.5% and 3.7%. Table 1Characteristics of the patients AllGroup 1Group 2Number351520Gender: male16 (46%)8 (53%)8 (40%)Disease course: relapsing remitting/secondary progressive31/413/218/2Age: mean (sd) in years40 (9)43 (10)37 (8)Disease duration: mean (SD) in years11 (7)12 (9)11 (6)EDSS: median (IQR)3.0 (1.5--4.0)3.0 (1.5--4.5)3.0 (2.0--4.0)SD = standard deviation; IQR = interquartile rangeTable 2The NAA/Cr ratios in the centrum semiovale at week 0 and week 4: mean (SD)  Week 0Week 4p- value^\*^All (N = 35)NAA/Cr white matter2.27 (0.26)2.26 (0.25)0.60NAA/Cr grey matter1.90 (0.23) ^\#^1.88 (0.21)0.42Cho/Cr white matter1.05 (0.13)1.03 (0.15)0.11Cho/Cr grey matter0.98 (0.12) ^\#^0.98 (0.13)0.60Group 1 (N = 15)NAA/Cr white matter2.45 (0.26)2.45 (0.25)0.82NAA/Cr grey matter2.08 (0.23) ^\#^2.03 (0.20)0.30Group 2 (N = 20)NAA/Cr white matter2.14 (0.15)2.13 (0.14)0.53NAA/Cr grey matter:1.76 (0.11) ^\#^1.77 (0.12)0.87^\*^p value: comparison week 0 with week 4^\#^p \< 0.001: comparison of grey matter with white matterSD = standard deviation

Discussion {#Sec7}
==========

Several small clinical trials in MS patients have used NAA/Cr ratios at the centrum semiovale as surrogate outcome measure \[[@CR12]--[@CR16]\]. Narayanan et al. reported an increase in NAA/Cr in ten relapsing MS patients after being treated with interferon β for 12 months \[[@CR12]\]. Khan et al. reported an elevation of NAA/Cr in 18 patients in a large central brain volume after 2 years of treatment with glatiramer acetate \[[@CR15]\]. An increase in NAA/Cr at the centrum semiovale in 11 MS patients after 2 weeks of treatment with fluoxetine was observed \[[@CR16]\]. These studies suggest beneficial effects of therapy on axonal functioning or integrity. However, interpretation of the results is hampered by a lack of studies assessing reproducibility of NAA/Cr measurements in MS patients.

One study in five healthy subjects, assessing intraday and interday reproducibility of NAA/Cr ratios in the centrum semiovale, found CVs ranging between 5.1% and 7.2% \[[@CR17]\]. Another study found a mean CV of 3.7% in six healthy subjects scanned twice, within 15 days apart, at a large volume of supratentorial brain \[[@CR18]\]. Our study for the first time shows good short-term (4-week apart) reproducibility of NAA/Cr ratio measurements in the centrum semiovale of patients with MS.

In agreement with previous studies, NAA/Cr ratios in grey matter were lower than in white matter \[[@CR19], [@CR20]\]. Patients scanned cranially of the ventricles had lower NAA/Cr and Cho/Cr ratios compared to patients scanned with the ventricles partially included. Since the corpus callosum has the highest white matter NAA/Cr and Cho/Cr ratios, the larger area of the corpus callosum included in the VOI when scanning more caudally might explain this difference \[[@CR21]\]. This underlines the importance of correct positioning of the VOI and voxel selection in longitudinal MRS studies.

Our study indicates that NAA/Cr ratio measurements with ^1^H-MRS at the centrum semiovale can be used as a reliable surrogate marker of cerebral tissue integrity in longitudinal MS studies. Selecting the VOI above the ventricles is preferred above placing the VOI partially in the ventricles.

This study was sponsored by Multiple Sclerosis anders (Amsterdam, The Netherlands).
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